Ascletis Strategy Begins To Reach Fruition In Deal With Alnylam For HCC Candidate

U.S.-China hybrid Ascletis is in-licensing rights to Phase II-ready RNA-interference program ALN-VSP from Alnylam with an eye on developing a groundbreaking therapy for an underserved indication that hits especially hard in China.